Jean-Luc M. Lemercier - 03 May 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, EMEACLA and JAPAC
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
03 May 2024
Net transactions value
-$25,227
Form type
4
Filing time
06 May 2024, 19:18:04 UTC
Previous filing
01 May 2024
Next filing
09 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Tax liability $3,147 -37 -0.02% $85.06 173,812 03 May 2024 Direct
transaction EW Common Stock Options Exercise $0 +4,157 +2.4% $0.000000 177,969 04 May 2024 Direct F1
transaction EW Common Stock Tax liability $22,080 -259 -0.15% $85.25 177,710 06 May 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -4,157 -100% $0.000000* 0 04 May 2024 Common Stock 4,157 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.